Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorSolmaz, V.
dc.contributor.authorKaya, M.
dc.contributor.authorUslu, F.B.
dc.contributor.authorAtasoy, O.
dc.contributor.authorErbaş, O.
dc.date.accessioned2022-11-04T19:55:45Z
dc.date.available2022-11-04T19:55:45Z
dc.date.issued2022
dc.identifier.issn0894-1939
dc.identifier.urihttps://doi.org/10.1080/08941939.2020.1809751
dc.identifier.urihttp://hdl.handle.net/11446/4618
dc.description.abstractAim: Our aim was to investigate the possible neuroprotective properties of papaverine in sepsis-induced critical illness neuropathy (SCIN) through the evaluation of various inflammatory biochemical markers, including interleukin 6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor-alpha (TNF-α), and oxidative stress biomarkers, such as malondialdehyde (MDA) and lactic acid. Additionally, evaluation of the HMGB1/RAGE interactions in SCIN was another target of this research. Method: To create a sepsis model, a procedure involving intraperitoneal injection of feces was performed on 48 rats. The rats were divided into four equal groups: sham operated, controls and those receiving 20 and 40 mg/kg/day papaverine. After five-day treatments, compound muscle action potential (CMAPs) with electroneuromyography (ENMG) was recorded in all rats. Following ENMG evaluations, the plasma levels of sRAGE, HMGB1, TNF-α, IL-6, CRP, MDA and lactic acid were measured. Results: TNF-α, CRP, IL-6, HMGB1, MDA, and lactic acid levels were significantly elevated in the SCIN group, and sRAGE levels were significantly decreased. In recipients of papaverine (20 and 40 mg/kg) treatment, these biochemical findings were improved. Furthermore, electrophysiological findings also showed significant improvement in both 20 and 40 mg/kg papaverine treated groups. Conclusion: Papaverine demonstrates neuroprotective effects in a rat model of SCIN. Considering its anti-inflammatory and antioxidant properties, papaverine’s neuroprotective effects possibly stem from the suppression of the RAGE-HMGB1 axis. (Figure presented.). © 2020 Taylor & Francis Group, LLC.en_US
dc.language.isoengen_US
dc.publisherTaylor and Francis Ltd.en_US
dc.relation.ispartofJournal of Investigative Surgeryen_US
dc.identifier.doi10.1080/08941939.2020.1809751en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectand lactic aciden_US
dc.subjectCMAPen_US
dc.subjectCritical illness polyneuropathyen_US
dc.subjectCRPen_US
dc.subjectHMGB1en_US
dc.subjectIL-6en_US
dc.subjectMDAen_US
dc.subjectpapaverineen_US
dc.subjectsRAGEen_US
dc.subjectTNF-αen_US
dc.subjectadvanced glycation end product receptoren_US
dc.subjectC reactive proteinen_US
dc.subjecthigh mobility group B1 proteinen_US
dc.subjectinterleukin 6en_US
dc.subjectketamineen_US
dc.subjectlactic aciden_US
dc.subjectmalonaldehydeen_US
dc.subjectpapaverineen_US
dc.subjectthiobarbituric acid reactive substanceen_US
dc.subjecttumor necrosis factoren_US
dc.subjectxylazineen_US
dc.subjectadulten_US
dc.subjectanimal experimenten_US
dc.subjectanimal modelen_US
dc.subjectanimal tissueen_US
dc.subjectantioxidant activityen_US
dc.subjectArticleen_US
dc.subjectcontrolled studyen_US
dc.subjectelectroneuromyographyen_US
dc.subjectelectrophysiologyen_US
dc.subjectenzyme linked immunosorbent assayen_US
dc.subjectfecesen_US
dc.subjectlipid peroxidationen_US
dc.subjectmaleen_US
dc.subjectmuscle action potentialen_US
dc.subjectneuropathyen_US
dc.subjectneuroprotectionen_US
dc.subjectnonhumanen_US
dc.subjectoxidative stressen_US
dc.subjectprotein blood levelen_US
dc.subjectraten_US
dc.subjectsepsisen_US
dc.subjecttemperatureen_US
dc.titlePapaverine Has Therapeutic Potential for Sepsis-Induced Neuropathy in Rats, Possibly via the Modulation of HMGB1-RAGE Axis and Its Antioxidant Prosperitiesen_US
dc.typearticleen_US
dc.identifier.issue1en_US
dc.identifier.volume35en_US
dc.identifier.startpage7en_US
dc.identifier.endpage13en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.department-tempSolmaz, V., Department of Neurology, Memorial Hizmet Hospital, Istanbul, Turkey; Kaya, M., Department of Internal Medicine, Memorial Hizmet Hospital, Istanbul, Turkey; Uslu, F.B., Department of Anesthesiology, Batman State Hospital, Batman, Turkey; Atasoy, O., Radiation Oncology, Kartal Dr. Lutfi Kırdar Traning and Research Hospital, Istanbul, Turkey; Erbaş, O., Medical Faculty, Department of Physiology, Demiroğlu Bilim University, Istanbul, Turkeyen_US
dc.identifier.pmid32842806en_US
dc.identifier.scopus2-s2.0-85089863009en_US
dc.authorscopusid55357225500
dc.authorscopusid57542543400
dc.authorscopusid57076695100
dc.authorscopusid57216297567
dc.authorscopusid55469991100


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster